Benutzerspezifische Werkzeuge

Studien

Studien

  

Für Patienten

  

Aktuell klinische Studien zu folgenden Indikationen:

Prostatakarzinom

  • CheckMate 650: Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer


Blasenkarzinom

  • Keynote-866: Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC)
  • Keynote-905: Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer


Nierenzellkarzinom

  • Exelixis XL184-313: A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
  • Cabopoint: A Phase II, Multicentre, Open-Label Study of Cabozantinib as 2nd Line Treatment in Subjects with Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors

Urothelkarzinom

  • THOR: A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
  • Nektar 18-214-10 / CA045-012A:  A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10)

 

weitere Informationen finden Sie unter: ClinicalTrials.gov

Sofern Sie in diesem Zusammenhang Fragen haben oder eventuell an einer der Studien in unserer Klinik teilnehmen möchten, setzen Sie sich bitte mit uns in Verbindung.
 

Kontakt:

Ärztlicher Leiter der Studienzentrale: Prof. Dr. med. Carsten Grüllich 

Studienkoordinatoren:: Frau Döring, Frau Grempel, Herr Raupach

Tel.: +49 (351) 458 - 4425           Fax: +49 (351) 458-7280